Assessment of metabolic response to pre-operative treatment of rectal cancer

Affiliations

01 July 2010


Abstract

In the era of targeted therapy and high precision radiotherapy for patients with cancer, tailoring and individualization of treatment is needed more and more. In part to avoid ineffective administration of a toxic treatment to a patient that unlikely to get any benefit of it. And also to decrease the expenses of treatment and saving the drugs and resources to patients that deserve. Many predictive factors and markers are searched and well-known in many malignancies, but still rectal cancer lacks such predictors. As the pre-operative chemoradiotherapy is becoming the standard of care of treating patients with locally advanced rectal carcinoma, a predictive factor, or at least an early indicator, of patient's response to treatment is needed. First, it may help to modulate the pre-operative treatment by employing another chemotherapeutic or targeted agent e.g. oxaloplatin or cetuximab instead of the standard fluorouracil compounds. It may also help to avoid continuation of unnecessary protracted course of radiotherapy for 5-6 weeks for a patient who is unlikely to achieve a satisfactory response. This will help to avoid the definite toxicity of pelvic irradiation and avoid wasting time before going to surgery. Here comes the role of imaging techniques in predicting the metabolic response such as functional computerized tomography (CT) and magnetic resonance imaging (MRI) or positron-emission tomography (PET) scan. In this review we will go through the principles, indications and benefits of employing such techniques in the assessment of response to pre-operative chemoradiotherapy of rectal cancer.


Similar articles

The metabolic response using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer.

Yoon MS, Ahn SJ, Nah BS, Chung WK, Song JY, Jeong JU, Nam TK.Radiother Oncol. 2011 Jan;98(1):134-8. doi: 10.1016/j.radonc.2010.10.012. Epub 2010 Oct 30.PMID: 21040991

Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.

Shanmugan S, Arrangoiz R, Nitzkorski JR, Yu JQ, Li T, Cooper H, Konski A, Farma JM, Sigurdson ER.Ann Surg Oncol. 2012 Jul;19(7):2178-85. doi: 10.1245/s10434-012-2248-z. Epub 2012 Mar 7.PMID: 22395978

Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT.

Ippolito D, Monguzzi L, Guerra L, Deponti E, Gardani G, Messa C, Sironi S.Abdom Imaging. 2012 Dec;37(6):1032-40. doi: 10.1007/s00261-011-9839-1.PMID: 22270580

PET monitoring of therapy response in head and neck squamous cell carcinoma.

Schöder H, Fury M, Lee N, Kraus D.J Nucl Med. 2009 May;50 Suppl 1:74S-88S. doi: 10.2967/jnumed.108.057208. Epub 2009 Apr 20.PMID: 19380408 Review.

Mucin-Containing Rectal Cancer: A Review of Unique Imaging, Pathology, and Therapeutic Response Features.

Childs DD, Rocha Lima CMSP, Zhou Y.Semin Roentgenol. 2021 Apr;56(2):186-200. doi: 10.1053/j.ro.2020.07.010. Epub 2020 Jul 30.PMID: 33858645 Review. No abstract available.


KMEL References